Alonzo Williams, MD
Gastroenterology · Little Rock, ARNPI 1326018581
Payments from drug & device makers
Across 626 payments — averaging $1737.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$580K
- AbbVie$217K
- Gilead$94K
- Bausch Health US, LLC$90K
- Novo Nordisk AS$49K
- Janssen Research & Development, LLC$32K
- plus $26K from 25 others
Across 1 payment — averaging $86,518 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$87K
What the payments were for
- Food & beverage$5,691100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 106 | $579,928 |
| AbbVie(2 entities) | 172 | $216,516 |
| Gilead | 52 | $94,362 |
| Bausch Health US, LLC | 52 | $89,753 |
| Novo Nordisk AS | 124 | $49,140 |
| Janssen Research & Development, LLC | 15 | $31,727 |
| AstraZeneca | 2 | $10,700 |
| Intercept Pharma Europe Ltd. | 3 | $7,889 |
| Madrigal Pharmaceuticals | 2 | $4,530 |
| Biotronik Inc. | 12 | $674 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $580 |
| Ipsen Bioscience Inc. | 4 | $308 |
| Abbott | 4 | $262 |
| E.r. Squibb & Sons, L.L.C. | 1 | $159 |
| Redhill Biopharma Inc. | 7 | $132 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Bayer | 7 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Johnson & Johnson | 4 | $81 |
| Merck | 5 | $80 |
| Evoke Pharma, Inc. | 3 | $49 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Mauna Kea Technologies, Inc. | 1 | $25 |
| Micro-tech Endoscopy USA, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| Olympus America Inc. | 1 | $14 |
| Dova Pharmaceuticals | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$472
- LINZESS$247
- Acticor$165
- Edora$165
- Rivacor$165
- Solia$165
- BioMonitor$165
- Fortify Assura, Ellipse ICD$161
- STELARA$125
- Rivacor 7 DR-T$106
- XIFAXAN$106
How this compares
$1,087,415 in reported general payments places this provider in the 95th percentile of 108 gastroenterology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 97 | $74,195 |
| CreonLipase/Protease/Amylase | 28 | $64,157 |
| Omeprazole | 2,087 | $41,591 |
| Famotidine | 486 | $9,662 |
| Dexlansoprazole DrDexlansoprazole | 39 | $9,250 |
| Sucralfate | 33 | $6,726 |
| Dicyclomine Hcl | 214 | $4,173 |
| Promethazine Hcl | 195 | $3,724 |
| Pantoprazole Sodium | 343 | $3,594 |
| Lubiprostone | 34 | $2,709 |
| Ondansetron Hcl | 67 | $1,905 |
| Megestrol Acetate | 35 | $1,884 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $810 |
| Hydrocortisone | 54 | $770 |
| Procto-Med HcHydrocortisone | 39 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $216,516 | $138,352125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 gastroenterology providers in Arkansas.
Other gastroenterology in Little Rock
- Glenn DavisLittle Rock$2.7M
- John BaberLittle Rock$1.8M
- Louis VelezLittle Rock$533K
- Angelo CoppolaLittle Rock$523K
- Meenakshi BudhrajaLittle Rock$85K
- Jonathan DranoffLittle Rock$72K
- Ali KhanLittle Rock$49K
- Keith MorrisLittle Rock$41K
- Abdalla TahiriLittle Rock$25K
- Jaymie PenningtonLittle Rock$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.